Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Neoplasms × dostarlimab × Clear all

Phase

Phase 1 7 Phase 2 5 Phase 3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Melanoma 2 Endometrial Neoplasms 2 Uterine Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Rhabdomyosarcoma 1 Rectal Neoplasms 1 Osteosarcoma 1 Oropharyngeal Neoplasms 1 Non-Squamous Non-Small Cell Lung Cancer (NSCLC) 1 Neoplasms 1 Multiple Myeloma 1 Mouth Neoplasms 1 Lung Neoplasms 1 Laryngeal Diseases 1 Hodgkin Disease 1 Hepatoblastoma 1 Head and Neck Neoplasms 1 Glioblastoma 1 Fibrolamellar hepatocellular carcinoma 1 Ependymoma 1 Diffuse Intrinsic Pontine Glioma 1 Carcinoma, Squamous Cell 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Hepatocellular 1 Carcinoma 1

Interventions

pembrolizumab 37 Nivolumab 24 Gemcitabine 24 Paclitaxel 16 Carboplatin 14 Cyclophosphamide 12 Cisplatin 12 Ipilimumab 10 Capecitabine 10 Irinotecan 8 Docetaxel 8 Dexamethasone 8 Bevacizumab 8 130-nm albumin-bound paclitaxel 8 Rituximab 7 Albumin-Bound Paclitaxel 7 Temozolomide 6 Sorafenib 6 Pemetrexed 6 Cetuximab 6 Azacitidine 6 Ascorbic Acid 6 spartalizumab 5 lenvatinib 5 fludarabine 5 cemiplimab 5 Radiotherapy 5 ibrutinib 4 avelumab 4 atezolizumab 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06796907 2025-10-14

BEHOLD-2

GlaxoSmithKline

Phase 1/2 Recruiting

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡